shortagewatch

Home / Companies / B. Braun

Company family · HQ DE

B. Braun: medicine shortages

private

As of 2 Nov 2026, 49 B. Braun products have a reported shortage across 10 countries, covering 17 medicines.

Products short49rank #37 of 464
Medicines17active ingredients
Countries10/16
New in 90 days18+12 vs market pace
Typical duration20 monthsmedian so far
Manufacturing46%demand-driven 39%

Where

United States19Germany1Italy13Spain1Austria4Belgium2Switzerland1Czechia4Norway2Sweden2

Which therapeutic classes

Blood16Nervous system11Dermatologicals4Anti-infectives4Various1Musculoskeletal system1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
B. BraunB. Braun: Manufacturing problem 13 (27%)27%B. Braun: Increased demand 11 (22%)22%B. Braun: Active ingredient shortage 1 (2%)B. Braun: Other 3 (6%)6%B. Braun: Not stated 21 (43%)43%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

025710Dec: 0Jan ’25: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 0Jul: 0Aug: 1AugSep: 0Oct: 0Nov: 0NovDec: 0Jan ’26: 0Feb: 0FebMar: 1Apr: 1May: 1MayJun: 1Jul: 1Aug: 2AugSep: 6Oct: 9Nov: 1Nov

Long-run trend in Canada

Canada dashboard
0257102017: 4420172018: 2220182019: 7720192021: 4420212025: 1120252026: 112026

Canada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158B. Braun49

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7B. Braun: 49 / 17B. Braun

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Electrolytes1020 May 2022Increased demand8/16
Povidone-Iodine412 Mar 2026Manufacturing problem4/16
Lidocaine325 Oct 2017Not stated9/16
Fluconazole215 Sep 2026Manufacturing problem12/16
Glucose214 Feb 2022Not stated1/16
Heparin214 Nov 2017Other5/16
Paracetamol21 Oct 2026Manufacturing problem10/16
Ropivacaine231 Aug 2026Increased demand9/16
Amikacin116 Sep 2026Manufacturing problem4/16
Combinations12 Nov 2026Increased demand2/16
Dexmedetomidine131 Aug 2026Not stated4/16
Electrolytes with Carbohydrates11 Sep 2026Other5/16
Etomidate128 Sep 2026Active ingredient shortage3/16
Gentamicin114 Oct 2026Increased demand3/16
Ibuprofen112 Oct 2026Manufacturing problem8/16
Propofol123 Dec 2026Increased demand6/16
Remifentanil17 Oct 2026Manufacturing problem5/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.